Last reviewed · How we verify
NVX-CoV2373 + NVX-CoV2540
A bivalent recombinant protein vaccine that elicits immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.
A bivalent recombinant protein vaccine that elicits immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19. Used for Prevention of COVID-19 in adults (Phase 3 development).
At a glance
| Generic name | NVX-CoV2373 + NVX-CoV2540 |
|---|---|
| Also known as | Prototype/BA.5 Bivalent Vaccine |
| Sponsor | Novavax |
| Drug class | Recombinant protein vaccine |
| Target | SARS-CoV-2 spike protein (original strain and Omicron variant) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
NVX-CoV2373 and NVX-CoV2540 are recombinant nanoparticle vaccines expressing spike proteins from the original SARS-CoV-2 strain and Omicron variant, respectively. When administered together, they stimulate both humoral and cellular immune responses to provide broader protection against multiple circulating variants of SARS-CoV-2.
Approved indications
- Prevention of COVID-19 in adults (Phase 3 development)
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Headache
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVX-CoV2373 + NVX-CoV2540 CI brief — competitive landscape report
- NVX-CoV2373 + NVX-CoV2540 updates RSS · CI watch RSS
- Novavax portfolio CI